Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03673124 · ClinicalTrials.gov registry record · Phase 2
Ribociclib and Letrozole Treatment in Ovarian Cancer
A Phase 2 study of Low Grade Serous Carcinoma, sponsored by Gynecologic Oncology Group.
- Active
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
- 20
- Study locations
NCT03673124: Active Phase 2 study of Low Grade Serous Carcinoma, sponsored by Gynecologic Oncology Group.
NCT03673124 is a Phase 2 study of Low Grade Serous Carcinoma that is active but no longer recruiting, run by Gynecologic Oncology Group. The registered enrollment target is 51 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03673124, a Phase 2 study of Low Grade Serous Carcinoma, is active but no longer recruiting, sponsored by Gynecologic Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
Primary Outcome
ORR was defined as the percentage of participants in the analysis population who achieved a complete response or partial response, as assessed by RECIST 1.1.
Conditions Studied
Interventions
- DRUG Letrozole
- DRUG Ribociclib
Study Locations (20)
Florida
- UF Heath - Gainesville
- Moffitt Cancer Center - Tampa
New Jersey
- Hackensack University Medical Center - Hackensack
- The Valley Hospital Inc. - Ridgewood
New Mexico
- New Mexico Cancer Care Alliance/University of New Mexico Comprehensive Cancer Center - Albuquerque
- Southwest Gynecologic Oncology Associates - Albuquerque
Ohio
- Miami Valley Hospital - Centerville
- The Ohio State Comprehensive Cancer Center - Columbus
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
- Oklahoma Cancer Care Specialists and Research Institute , LLC - Tulsa
Pennsylvania
- Western Pennsylvania Hospital/West Penn Hospital - Pittsburgh
- Abington Memorial Hospital - Willow Grove
California
- University of California, San Francisco - San Francisco
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2019-05-20 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
What the registry record for NCT03673124 still lists
NCT03673124 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 51 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Low Grade Serous Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Letrozole is the first listed.
NCT03673124 names 20 study sites across 14 states, led by Florida, New Jersey, New Mexico.
Frequently Asked Questions
What is clinical trial NCT03673124 about?
NCT03673124 is a clinical study titled "Ribociclib and Letrozole Treatment in Ovarian Cancer". The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
What is the current status of trial NCT03673124?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2019-05-20. Estimated completion is 2026-12-31.
What conditions does trial NCT03673124 study?
This clinical trial studies the following conditions: Low Grade Serous Carcinoma.
What interventions are being tested in trial NCT03673124?
The interventions under investigation include: Letrozole (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT03673124?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03673124 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03673124's enrollment target sits among peer trials
51 1190th of 2000 higher than 806 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02701153 · 51 participants · NA
Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort
- NCT03663790 · 51 participants · NA
Effects of Gait Retraining on Lower Extremity Biomechanics
- NCT03874052 · 51 participants · Phase 1
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- NCT04704661 · 51 participants · Phase 1
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI